External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
Open accessAbstract
Background. Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC). Aim. To independently evaluate the predictive performance of the URS model. Methods. We used a cohort of Slovak and Croatian treatment‐naïve PBC patients to quantify the discrimination ability using the area under receiver operating characteristic curve (AUROC) and its 95% confidence interval (CI). Furthermore, we evaluated the calibration using calibration belts. The primary outcome was treatment response after 12 months of UDCA therapy defined as values of alkaline phosphatase ≤1.67 × upper limit of normal. Results. One hundred and ninety‐four patients were included. Median pretreatment age was 56 years (interquartile range 49–62). Treatment response was achieved in 79.38% of patients. AUROC of the URS was 0.81 (95% CI 0.73–0.88) and the calibration belt revealed that response rates were correctly estimated by predicted probabilities. Conclusion. Our results confirm that the URS can be used in treatment‐naïve PBC patients for estimating the treatment response probability after 12 months of UDCA therapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A predictive model of response to ursodeoxycholic acid treatment was developed based on pretreatment clinical factors and biochemistries and was validated in other cohorts.
“A predictive model of response to ursodeoxycholic acid treatment was developed based on pretreatment clinical factors and biochemistries, 121 and was validated in other cohorts.122,123”
From Primary biliary cholangitis. (2024) · cites this paper as [122]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480 · cited 9× · see citing works
“One hundred sixty-seven patients were AMA positive (86.08%), and six patients (3.09%), both AMA and ANA negative, were diagnosed by meeting the following criteria only: (1) elevated ALP and (2) histological signs after liver biopsy.”
InfluentialA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · see citing works
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 347 · see citing works
Harms, M. H., van Buuren, H. R., Corpechot, C., Thorburn, D., Janssen, H. L. A., Lindor, K. D., Hirschfield, G. M., Parés, A., Floreani, A., Mayo, M. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.001 · Cited by 289 · see citing works
Carbone, M., Nardi, A., Flack, S., Carpino, G., Varvaropoulou, N., Gavrila, C., Spicer, A., Badrock, J., Bernuzzi, F., Cardinale, V., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30163-8 · Cited by 155 · see citing works
Flagged first, then by citations
Research works printed but not linked: 19
- [1]Boonstra K. Beuers U. Ponsioen C. Y. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review Journal of Hepatology 2012 56 5 1181 1188 10.1016/j.jhep.2011.10.025 2-s2.0-84859725557 22245904 · DOI · Paper page
- [2]Drazilova S. Babinska I. Babinska I. Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia International Journal of Public Health 2020 65 5 683 691 10.1007/s00038-020-01391-6 32500239 · DOI
- [3]Madir A. Božin T. Mikolašević I. Epidemiological and clinical features of primary biliary cholangitis in two Croatian regions: a retrospective study Croatian Medical Journal 2019 60 6 494 502 10.3325/cmj.2019.60.494 31894914 PMC6952898 · DOI
- [4]Carbone M. Milani C. Gerussi A. Ronca V. Cristoferi L. Invernizzi P. Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets Journal of Hepatology 2020 73 4 965 966 10.1016/j.jhep.2020.05.041 32709365 · DOI
- [6]Gatselis N. K. Goet J. C. Zachou K. Factors associated with progression and outcomes of early stage primary biliary cholangitis Clinical Gastroenterology and Hepatology 2020 18 3 684 692 10.1016/j.cgh.2019.08.013 31419573 · DOI
- [9]Parés A. Caballería L. Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid Gastroenterology 2006 130 3 715 720 10.1053/j.gastro.2005.12.029 2-s2.0-33644854254 16530513 · DOI · Paper page
- [10]Örnolfsson K. T. Lund S. H. Olafsson S. Bergmann O. M. Björnsson E. S. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study Scandinavian Journal of Gastroenterology 2019 54 5 609 616 10.1080/00365521.2019.1606931 2-s2.0-85065720713 31074667 · DOI
- [11]Corpechot C. Chazouillères O. Rousseau A. A placebo-controlled trial of bezafibrate in primary biliary cholangitis New England Journal of Medicine 2018 378 23 2171 2181 10.1056/NEJMoa1714519 2-s2.0-85048328032 29874528 · DOI · Paper page
- [14]Thrift A. P. Kanwal F. El-Serag H. B. Prediction models for gastrointestinal and liver diseases: too many developed, too few validated Clinical Gastroenterology and Hepatology 2016 14 12 1678 1680 10.1016/j.cgh.2016.08.026 2-s2.0-84995624331 27574756 · DOI
- [15]Collins G. S. Reitsma J. B. Altman D. G. Moons K. G. M. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) Circulation 2015 131 2 211 219 10.1161/circulationaha.114.014508 2-s2.0-84927910843 25561516 PMC4297220 · DOI · Paper page
- [16]Yagi M. Matsumoto K. Komori A. A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis Liver International 2020 40 8 1926 1933 10.1111/liv.14534 32438508 · DOI · Paper page
- [17]Kumagi T. Guindi M. Fischer S. E. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis American Journal of Gastroenterology 2010 105 10 2186 2194 10.1038/ajg.2010.216 2-s2.0-77957851364 20502446 · DOI · Paper page
- [18]Finazzi S. Poole D. Luciani D. Cogo P. E. Bertolini G. Calibration belt for quality-of-care assessment based on dichotomous outcomes PLoS One 2011 6 2 e16110 10.1371/journal.pone.0016110 2-s2.0-79952013335 PMC3043050 21373178 · DOI
- [19]Chen J. Xue D. Gao F. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment European Journal of Gastroenterology and Hepatology 2018 30 11 1352 1360 10.1097/meg.0000000000001186 2-s2.0-85054724236 29889683 · DOI
- [20]Dyson J. Jones D. Diagnosis and management of patients with primary biliary cirrhosis Clinical Liver Disease 2014 3 3 52 55 10.1002/cld.320 2-s2.0-84897406778 30992885 PMC6448699 · DOI
- [21]Remmel T. Remmel H. Uibo R. Salupere V. Primary biliary cirrhosis in Estonia with special reference to incidence, prevalence, clinical features, and outcome Scandinavian Journal of Gastroenterology 1995 30 4 367 371 10.3109/00365529509093292 2-s2.0-0028931952 7610354 · DOI
- [22]Gatselis N. K. Zachou K. Lygoura V. Geoepidemiology, clinical manifestations and outcome of primary biliary cholangitis in Greece European Journal of Internal Medicine 2017 42 81 88 10.1016/j.ejim.2017.05.006 2-s2.0-85019911422 28535947 · DOI
- [23]Delgado J.-S. Vodonos A. Delgado B. Primary biliary cirrhosis in Southern Israel: a 20year follow up study European Journal of Internal Medicine 2012 23 8 e193 e198 10.1016/j.ejim.2012.09.004 2-s2.0-84869011461 23022449 · DOI
- [24]Lu M. Li J. Haller I. V. Factors associated with prevalence and treatment of primary biliary cholangitis in United States health systems Clinical Gastroenterology and Hepatology 2018 16 8 1333 1341 10.1016/j.cgh.2017.10.018 2-s2.0-85044601711 29066370 · DOI
Cited by
Sorted by citations
Tanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01303-5 · Cited by 177 · see citing works
- Authors
- Gazda, J., Janicko, M., Drazilova, S., Grgurevic, I., Kanizaj, T. F., Koller, T., Bodorovska, B., Mijic, M., Mikolasevic, I., Stromar, I. K., Kucinsky, B., Gazda, M., & Jarcuska, P.
- Affiliations
- University of Pavol Jozef Šafárik (SK)
- University Hospital Bratislava (SK)
- Martin University Hospital (SK)
- Technical University of Košice (SK)
- ORCID
- Venue
- Canadian Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2021-01
- Volume
- 2021
- Issue
- 1
- Pages
- 9928065-9928065
- ISSN
- 2291-2789 (ISSN-L)
- 2291-2797
- PMC
- PMC8245238
- OpenAlex
- W3175542580
- Cited by
- 6
- References
- 5
- Citations by year
- 2024: 3 · 2023: 1 · 2022: 2
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Canadian Journal of Gastroenterology and Hepatology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Gallbladder and Bile Duct Disorders
- Keywords
- primary biliary cirrhosis, ursodeoxycholic acid, treatment response prediction, prognostic model, external validation, discrimination (statistics), calibration, alkaline phosphatase, treatment-naive patients, Croatian patients
- MeSH terms
- Cholagogues and Choleretics, Humans, Liver Cirrhosis, Biliary, Middle Aged, Ursodeoxycholic Acid, Cohort Studies, Slovakia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
